farnesyltransferas
regard
promis
drug
target
cancer
critic
membran
associ
sever
signal
transduct
protein
studi
novel
farnesyltransferas
inhibitor
identifi
virtual
screen
exhibit
stronger
potenc
ic
sunitinib
test
cancer
cell
line
preliminari
studi
mechan
reveal
induc
apoptosi
cell
arrest
cell
cycl
phase
alter
antiand
proapoptot
protein
lead
mitochondri
dysfunct
activ
antitumor
effect
probabl
relat
inhibit
farnesyltransferas
indic
molecular
dock
overal
novel
lead
compound
potent
antitumor
activ
deserv
structur
modif
cancer
still
remain
second
lead
caus
death
worldwid
cardiovascular
diseas
mani
class
antitumor
agent
especi
tyrosin
kinas
tk
inhibitor
introduc
market
last
decad
candid
develop
howev
given
emerg
drug
resist
low
success
rate
clinic
develop
discoveri
novel
chemic
compound
complet
new
mode
action
clearli
need
ra
gene
encod
protein
collect
known
ra
superfamili
involv
regul
prolifer
differenti
cell
adhes
apoptosi
cell
protein
small
g
protein
transduc
signal
cellsurfac
receptor
growth
factor
receptor
transmit
signal
sever
differ
pathway
ultim
affect
mitogen
function
dna
synthesi
cytoskelet
organ
lipid
metabol
disrupt
signal
transduct
pathway
mutat
ra
gene
involv
mani
tumor
type
farnesyl
type
lipid
modif
call
protein
prenyl
critic
biolog
function
includ
membran
associ
sever
signal
transduct
protein
oncogen
mutant
form
human
ra
superfamili
protein
associ
human
cancer
transform
abil
mutant
depend
upon
farnesyl
recent
farnesyltransferas
becom
popular
drug
target
inhibitor
farnesyltransferas
caus
tumor
regress
anim
current
evalu
clinic
trial
treatment
human
cancer
farnesyltransferas
inhibitor
fti
investig
clinic
trial
includ
lonafarnib
sarasar
tm
scheringplough
tipifarnib
zarnestra
tm
ortho
biotechproduct
merck
bristolmyerssquibb
salirasib
stran
transfarnesylthiosalycil
acid
ft
concordia
pharmaceut
howev
none
oncotarget
wwwimpactjournalscomoncotarget
yet
approv
fda
clinic
treatment
therefor
imper
develop
new
fti
computeraid
drug
design
one
effect
method
develop
new
drug
mani
report
indic
comput
method
timesav
effortsav
approach
discov
new
candid
includ
molecular
dock
virtual
screen
virtual
screen
vs
emerg
power
approach
complement
array
exist
highthroughput
screen
technolog
use
computeraid
vs
potenti
lead
rapidli
identifi
silico
order
narrow
rang
molecul
test
vitro
vivo
studi
virtual
screen
use
queri
inhous
chemic
databas
compound
screen
retriev
potenti
fti
virtual
screen
chemic
databas
serv
purpos
find
novel
potenti
lead
suitabl
develop
molecular
dock
technolog
increasingli
use
cours
drug
research
develop
repres
receptorbas
virtual
screen
paper
molecular
dock
experi
carri
use
discoveri
studio
softwar
accelri
inc
san
diego
ca
usa
fulli
autom
dock
tool
use
cdocker
protocol
employ
charmm
forc
field
investig
possibl
inhibitor
farnesyltransferas
cdocker
energi
proteinligand
interact
energi
best
pose
dock
receptor
compound
calcul
compar
compound
new
potent
farnesyltransferas
inhibitor
base
ethylenediamin
scaffold
result
found
highest
cdocker
energi
similar
structur
framework
crystal
inhibitor
compound
farnesyltransferas
shown
figur
accord
dock
result
activ
compound
compound
found
bind
activ
pocket
farnesyltransferas
receptor
similar
conform
figur
describ
parabenzonitril
moieti
compound
one
orient
toward
product
exit
groov
partial
stabil
stack
interact
figur
three
hydrogen
bond
interact
posit
consist
cdockerinteractionenergi
two
compound
farnesyltransferas
highest
cdockerinteractionenergi
compound
suggest
could
similar
affin
compound
farnesyltransferas
might
one
possibl
target
detail
synthet
pathway
compound
depict
scheme
treatment
ethambutol
emb
tertbutyldimethylsilyl
chlorid
tbdmscl
gave
desir
bistbdmsprotect
compound
coupl
result
diamin
intermedi
deprotect
hydroxyl
group
tetrabutylammonium
fluorid
tbaf
tetrahydrofuran
thf
yield
target
compound
scheme
preliminari
screen
antitumor
activ
first
investig
cytotox
activ
lung
adenocarcinoma
breast
cancer
prostat
carcinoma
liver
carcinoma
compound
evalu
vitro
antitumor
activ
aforement
four
human
cancer
cell
line
mtt
assay
inhibit
rate
ic
valu
compar
sunitinib
multitarget
receptor
tk
inhibitor
tabl
exhibit
remark
antitumor
activ
inhibit
rate
ic
better
sunitinib
inhibit
rate
ic
cancer
cell
line
thu
select
lead
compound
preliminari
mechan
studi
growth
inhibit
cell
understand
mechan
underli
action
effect
cell
cycl
examin
cell
treat
indic
concentr
h
stain
propidium
iodid
pi
follow
flow
cytometri
analysi
shown
figur
percentag
cell
phase
respect
significantli
higher
vehicl
treat
control
henc
inhibit
growth
cancer
cell
inhibit
cell
cycl
via
sphase
arrest
apoptosi
play
central
role
cancer
treatment
sinc
induct
cancer
cell
critic
success
therapi
thu
believ
apoptosi
assay
may
provid
import
inform
preliminari
investig
mode
action
impact
imbwwwimpactjournalscomoncotarget
annexin
vpi
stain
follow
flow
cytometri
analysi
shown
figur
treatment
cell
h
result
increas
apoptosi
ratio
untreat
vehicl
control
indic
abl
induc
apoptot
cell
death
cell
concentrationdepend
manner
order
determin
plausibl
pathway
trigger
cell
apoptosi
chang
mitochondri
membran
potenti
assess
uptak
iodid
lipophil
cation
fluoresc
dye
accumul
mitochondria
posit
correl
mitochondri
membran
potenti
cell
treat
differ
concentr
h
prior
stain
number
cell
collaps
mitochondri
membran
potenti
differ
cell
group
determin
flow
cytometr
analysi
shown
figur
percentag
cell
typic
apoptot
morpholog
increas
dosedepend
fashion
respect
result
reveal
incub
increas
number
cell
collaps
mitochondri
membran
potenti
induc
apoptosi
mitochondria
play
essenti
role
cell
death
signal
transduct
mitochondriadepend
apoptot
pathway
regul
famili
proand
antiapoptot
protein
induc
permeabil
mitochondri
outer
membran
result
activ
caspas
cascad
induct
apoptot
cell
death
explor
possibl
role
mitochondrialrel
pathway
apoptosi
effect
level
bax
examin
western
blot
analysi
shown
figur
treatment
show
concentrationdepend
effect
upregul
express
bax
downregul
addit
activ
concentrationdepend
manner
treatment
h
result
reveal
induc
apoptosi
cancer
cell
via
mitochondriadepend
pathway
repres
crystal
structur
farnesyltransferas
pdb
id
obtain
protein
databank
initi
pretreat
process
ligand
enzym
ligand
prepar
duplic
structur
remov
option
ioniz
chang
tautom
gener
isom
gener
lipinski
filter
gener
set
true
enzym
prepar
whole
enzym
select
water
remov
hydrogen
atom
ad
ph
theprotein
set
rang
defin
enzym
total
receptor
bind
site
defin
select
import
amino
acid
catalysi
gener
radiu
sphere
oper
defin
edit
bind
site
dock
compound
enzym
cdocker
done
use
default
paramet
pose
top
cdockerinteractionenergi
chosen
analyz
bind
featur
reagent
purchas
commerci
supplier
use
without
purif
unless
otherwis
indic
reaction
cours
monitor
tlc
silica
gel
precoat
merck
plate
develop
plate
examin
uv
lamp
nm
hnmr
cnmr
spectra
taken
bruker
spectromet
use
tm
intern
standard
dmsod
cdcl
use
solvent
mass
spectra
measur
agil
seri
solut
ethambutol
dihydrochlorid
mmol
et
n
ml
mmol
anhydr
dcm
ad
dropwis
solut
tertbutyldimthylsilyl
chlorid
g
mmol
anhydr
dcm
ml
addit
mixtur
stir
room
temperatur
h
wash
water
ml
satd
nahco
ml
brine
ml
organ
fraction
dri
anhydr
magnesium
sulfat
solvent
remov
vacuo
yield
g
colourless
oil
anhydr
potassium
carbon
g
mmol
ad
solut
g
mmol
mg
mmol
acetonitril
result
mixtur
reflux
overnight
reaction
mixtur
pour
water
ml
extract
dcm
ml
combin
organ
extract
wash
satd
nahco
ml
brine
ml
dri
anhydr
magnesium
sulfat
solvent
remov
vacuo
obtain
crude
reaction
mixtur
purif
perform
silica
flash
column
chromatographi
elut
dcmmeoh
afford
light
yellow
oil
g
solut
compound
g
mmol
thf
ml
tbaf
thf
ml
mmol
allow
react
room
temperatur
reaction
mixtur
concentr
purifi
silica
flash
column
chromatographi
vv
meoh
dcm
collect
fraction
evapor
afford
alcohol
white
solid
mg
cell
line
provid
nanj
keygen
biotech
inc
cell
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
contain
calf
serum
cs
grown
humidifi
atmospher
co
annexin
apoptosi
detect
kit
cell
cycl
detect
kit
mitochondri
membran
potenti
detect
kit
sdspage
gel
prepar
kit
enhanc
chemiluminesc
ecl
kit
purchas
nanj
keygen
biotech
co
ltd
nanj
china
dmso
mtt
purchas
sigmaaldrich
merck
millipor
darmstadt
germani
reagent
purchas
beyotim
institut
biotechnolog
jiangsu
china
cell
growth
inhibit
determin
use
colorimetr
mtt
assay
assay
conduct
plate
cell
densiti
cell
per
well
incub
period
h
cell
incub
differ
concentr
mgl
triplic
h
incub
cell
incub
medium
contain
mtt
h
formazan
crystal
dissolv
dmso
dark
blue
mtt
crystal
dissolv
agit
plate
room
temperatur
min
absorb
measur
nm
micropl
reader
olympu
japan
cell
seed
plate
treat
differ
concentr
h
apoptosi
detect
follow
procedur
cell
inocul
plate
process
accordingli
adher
cell
treat
h
cell
collect
trypsin
without
edta
wash
twice
pb
annexin
apoptosi
detect
kit
keygen
nanj
china
use
cell
stain
flow
cytometri
bectondickinson
fac
calibur
follow
manufactur
instruct
percentag
apoptot
cell
determin
use
fac
flow
cytometri
associ
softwar
beckman
experi
repeat
three
time
result
display
histogram
cell
logarithm
phase
growth
digest
trypsin
centrifug
count
wwwimpactjournalscomoncotarget
cell
inocul
plate
cell
process
accordingli
adher
whereaft
cell
collect
wash
pb
ethyl
alcohol
ad
fixat
overnight
supernat
remov
cell
wash
pb
rna
enzym
ad
cell
place
minut
digest
pi
ad
stain
cell
place
dark
minut
pistain
protoplast
measur
flow
cytometri
excit
wavelength
nm
cell
inocul
plate
process
accordingli
adher
cell
treat
h
cell
collect
wash
pb
resuspend
fresh
medium
contain
iodid
incub
minut
humidifi
atmospher
contain
co
cell
analyz
flow
cytometri
excit
wavelength
nm
cell
total
protein
extract
perform
follow
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
transmembran
antibodi
incub
color
develop
summari
new
compound
identifi
synthes
character
hnmr
cnmr
ms
found
consider
potenc
ic
better
sunitinib
four
cancer
cell
line
test
moreov
preliminari
studi
mechan
reveal
induc
apoptosi
cell
arrest
cell
cycl
phase
alter
antiand
proapoptot
protein
lead
mitochondri
dysfunct
activ
meanwhil
molecular
dock
studi
suggest
one
possibl
target
protein
farnesyltransferas
togeth
novel
conjug
potent
antitumor
activ
could
contribut
better
understand
structurebas
drug
design
facilit
drug
discoveri
base
structur
modif
sar
studi
enzym
inhibitori
activ
current
progress
